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Objectives This study aimed to determine the diagnostic accuracy of the 3 most commonly used noninvasive myocardial
perfusion imaging modalities, single-photon emission computed tomography (SPECT), cardiac magnetic reso-
nance (CMR), and positron emission tomography (PET) perfusion imaging for the diagnosis of obstructive coro-
nary artery disease (CAD). Additionally, the effect of test and study characteristics was explored.
Background Accurate detection of obstructive CAD is important for effective therapy. Noninvasive myocardial perfusion imag-
ing is increasingly being applied to gauge the severity of CAD.
Methods Studies published between 1990 and 2010 identified by PubMed search and citation tracking were examined. A
study was included if a perfusion imaging modality was used as a diagnostic test for the detection of obstructive
CAD and coronary angiography as the reference standard (50% diameter stenosis).
Results Of the 3,635 citations, 166 articles (n  17,901) met the inclusion criteria: 114 SPECT, 37 CMR, and 15 PET
articles. There were not enough publications on other perfusion techniques such as perfusion echocardiography
and computed tomography to include these modalities into the study. The patient-based analysis per imaging
modality demonstrated a pooled sensitivity of 88% (95% confidence interval [CI]: 88% to 89%), 89% (95% CI:
88% to 91%), and 84% (95% CI: 81% to 87%) for SPECT, CMR, and PET, respectively; with a pooled specificity of
61% (95% CI: 59% to 62%), 76% (95% CI: 73% to 78%), and 81% (95% CI: 74% to 87%). This resulted in a
pooled diagnostic odds ratio (DOR) of 15.31 (95% CI: 12.66 to 18.52; I2 63.6%), 26.42 (95% CI: 17.69 to 39.47;
I2 58.3%), and 36.47 (95% CI: 21.48 to 61.92; I2 0%). Most of the evaluated test and study characteristics did
not affect the ranking of diagnostic performances.
Conclusions SPECT, CMR, and PET all yielded a high sensitivity, while a broad range of specificity was observed. SPECT is
widely available and most extensively validated; PET achieved the highest diagnostic performance; CMR may
provide an alternative without ionizing radiation and a similar diagnostic accuracy as PET. We suggest that refer-
ring physicians consider these findings in the context of local expertise and infrastructure. (J Am Coll Cardiol
2012;59:1719–28) © 2012 by the American College of Cardiology Foundation
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Diagnostic Performance of SPECT, CMR, PET Perfusion May 8, 2012:1719–28Coronary artery disease (CAD)
is still the leading cause of death
in industrialized countries, and
the prevalence is expected to in-
crease worldwide (1–3). Ischemia
is a strong predictor of adverse
outcome such as future myocar-
dial infarctions, and detection of
ischemia is an important part of
the diagnostic strategy in current
guidelines (4–7). Moreover, a
normal single-photon emission to-
mography (SPECT), cardiac mag-
netic resonance (CMR), or posi-
tron emission tomography (PET)
perfusion scan indicates an excel-
lent prognosis with a low rate of
cardiac events (8–10). Noninva-
sive functional imaging modalities
such as SPECT, CMR, and PET
perfusion imaging are, therefore,
increasingly being performed for
the detection and risk stratification of obstructive CAD.
Previous meta-analyses have evaluated the individual
diagnostic performance of perfusion imaging modalities for
the detection of CAD as defined by invasive coronary
angiography (CA) (11–14). However, the different perfu-
sion techniques have not been compared directly. Thus, the
current meta-analysis aimed to compare the diagnostic
performance of the 3 most commonly used modalities for
myocardial perfusion imaging (i.e., SPECT, CMR, and
PET) and to provide an overview of test characteristics,
benefits, and drawbacks of each technique. In addition, the
effect of test and study characteristics on the diagnostic
accuracy of perfusion imaging techniques was explored.
Methods
Data sources and study selection. We searched the PubMed
database for English literature from January 1990 to February
010 on the diagnostic accuracy of myocardial perfusion
maging for the detection of CAD. We used the following
edical Subject Headings and search terms: “single-photon
mission computed tomography,” “magnetic resonance im-
ging,” “positron emission tomography,” “contrast echocar-
iography,” “perfusion echocardiography,” “computed to-
ography,” and “myocardial perfusion” in combination with
he exploded term “coronary artery disease.” The bibliogra-
hies of selected articles and relevant reviews were screened
or potentially suitable references. A perfusion imaging
odality was included in the meta-analysis if there were
10 studies reporting patient-based results of diagnostic
ccuracy. Therefore, myocardial perfusion echocardiography
nd computed tomography (CT) myocardial perfusion im-
Abbreviations
and Acronyms
CA  coronary angiography
CAD  coronary artery
disease
CMR  cardiac magnetic
resonance
CT  computed
tomography
DE  delayed enhancement
DOR  diagnostic odds
ratio
PET  positron emission
tomography
RDOR  relative diagnostic
odds ratio
SPECT  single-photon
emission computed
tomography
SROC  summary receiver-
operating characteristicging were not included in the current meta-analysis. nWe included a study if: 1) it assessed SPECT, CMR, or
PET perfusion imaging as a diagnostic test to evaluate
patients for the presence of CAD; 2) CAD was defined as
at least 50% diameter stenosis on CA; and 3) it reported
cases in absolute numbers of true positive, false positive, true
negative, and false negative results, or if these data were
derivable from the presented results. A study was eligible
regardless of whether patients were referred for suspected or
known CAD. Studies were excluded if they were conducted
with: 1) phantom-only models; 2) animals; 3) normal
healthy volunteers only without CA correlation; or 4) if they
included10 patients. Different articles by the same author
or research group were included for analysis only when it
was obvious that different patient samples were used.
Data extraction. First, identifying information about the
study such as first author, journal, and year of publication
was extracted. Further extracted variables consisted of pa-
tient characteristics, technical information and absolute
numbers of true negative, true positive, false negative, and
false positive test results. If available, data were recorded on
patient and coronary artery territory level (i.e., left anterior
descending, left circumflex, and right coronary artery).
Several studies used 1 cutoff value for CAD and, as a
consequence, reported 1 pair of sensitivity and specificity.
To improve the comparability of study results in the analysis
of overall diagnostic performance, we selected a cutoff value
of 50% whenever possible. However, if data were not
reported for a cutoff value of 50%, we selected the cutoff
value that was available (e.g., 70%). If a study presented
multiple sensitivity and specificity estimates for the selected
cutoff value due to different study protocols (e.g., exercise
versus pharmacological stress), the data of the protocol with
the highest estimates was extracted. In cases where 1
iagnostic technique was evaluated within a single publica-
ion (e.g., SPECT vs. CMR), each modality was considered
eparately. We also assessed the likelihood of verification
ias, which occurs when patients with a positive result on
he index test (i.e., the test under investigation) are referred
o the reference standard more often than patients with a
egative result. Four investigators (C.J., T.L., P.N., and
.S.) extracted data independently, and discrepancies were
esolved by consensus.
tatistical analysis. On the basis of the results from the
derived) 22 contingency tables, pooled measures for
iagnostic performance, such as sensitivity, specificity, di-
gnostic odds ratio (DOR), and area under the curve (AUC)
ith 95% confidence intervals (CIs) were calculated using
andom effects models. The pooled DOR for each imaging
odality was used for the construction of summary receiver
perating characteristic (SROC) curves. The SROC curves
ccount for the so-called threshold effect in diagnostic
tudies arising when studies use different cutoff points or
hresholds to define a positive or negative result. The DOR
ombines sensitivity and specificity into 1 measure for
iagnostic performance. A DOR of 1 means that a test has
o ability to discriminate. The higher the DOR, the better
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May 8, 2012:1719–28 Diagnostic Performance of SPECT, CMR, PET Perfusionthe ability of a test to discriminate between subjects with
and without the disease of interest. Relative diagnostic odds
ratios (RDOR) with 95% CI were calculated using meta-
regression random effects models to evaluate significant
differences in diagnostic performance between the 3 imag-
ing modalities (15).
The I2 index was used to test for heterogeneity between
tudy results. Significance of this index indicates that
ifferences between study results cannot solely be attributed
o sampling variation. Statistical heterogeneity was defined
SPECT C
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Figure 1 Flow Diagram of Literature Search
Of 3,635 potentially relevant citations, 166 articles met our inclusion criteria and
CMR  cardiac magnetic resonance; PET  positron emission tomography; SPECT
Diagnostic Performance of SPECT, CMR, and PET Perfusion ImaginTable 1 Diagnostic Performance of SPECT, CMR, and PET Perf
No. of Studies Sensitivity (95% CI) Spe
Patient basis
SPECT 105 88 (88–89)
CMR 27 89 (88–91)
PET* 11 84 (81–87)
Coronary territory basis
SPECT 45 69 (68–70)
CMR 17 84 (81–86)
PET† 7 77 (73–81)
*Positron emission tomography (PET) studies compared to cardiac magnetic resonance (CMR) stu
0.62 to 3.34; p  0.39). †PET studies compared to CMR studies on a coronary territory-based analysis: R
DOR  diagnostic odds ratio; SPECT  single-photon emission computed tomography.s an I2 statistic value of 50% (16). Differences in study
haracteristics between modalities can be a cause of consid-
rable heterogeneity (e.g., due to the use of different stressors or
racers) and can also affect the comparison of diagnostic
erformance between imaging modalities. Therefore, the dis-
ribution of study characteristics of SPECT, CMR, and PET
tudies were compared using the chi-square test to test for
ifferences in variables with nominal values, and the t test for
ndependent samples in case of continuous values (SPSS 17.0,
PSS Inc., Chicago, Illinois). Pooled estimates were calculated
779 Potentially 
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39 Articles retrieved 
for full text review
15 Articles 
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y (95% CI) DOR (95% CI) RDOR (95% CI) p Value
9–62) 15.31 (12.66–18.52) —
3–78) 26.42 (17.69–39.47) 1.67 (1.07–2.61) 0.05
4–87) 36.47 (21.48–61.92) 2.25 (1.05–4.84) 0.05
8–80) 11.75 (9.26–14.91) —
1–86) 24.11 (15.68–37.07) 2.58 (1.53–4.35) 0.001
4–90) 24.74 (15.57–39.30) 2.30 (1.10–4.77) 0.05
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Diagnostic Performance of SPECT, CMR, PET Perfusion May 8, 2012:1719–28for subgroups of studies that were defined according to specific
study characteristics. The RDORs with 95% CI were calcu-
lated to quantify the differences in pooled odds ratios between
subgroups. In addition to the comparison of subgroups within
a single imaging modality, the pooled DORs of the subgroups
were also compared between the different imaging modalities.
Meta-DiSc 1.4 was used for data analysis (17). Publication bias
was examined using funnel plots and Egger’s test (18).
Results
A PubMed database search and additional citation track-
ing of review and original articles resulted in 3,635
potentially relevant citations (Fig. 1). A total of 166
articles (n  17,901) met our inclusion criteria: 114 SPECT
(n  13,741), 37 CMR (n  2,841), and 15 PET studies
n  1,319). The study and population characteristics as
Figure 2 SPECT, CMR, and PET for Detecting CAD
Diagnostic performance of (A) single-photon emission computed tomography (SPE
(PET) for the detection of coronary artery disease (CAD) on a patient-based level: g
(SROC) curves. (A, B, C) Each dot represents a single study, with the size of the
(AUC) reflects the overall diagnostic performance and is expressed as a value bet
0.8659, 0.9055, and 0.9239 for SPECT, CMR, and PET, respectively. (D) Fitted S
CMR (blue line), and PET (red line).ell as a list of all studies included in the meta-analysis are
resented in the Appendix (see Online Tables 1 through 6
nd Online References).
iagnostic performance of myocardial perfusion imaging.
ooled estimates of sensitivity, specificity, and DOR of
he 3 perfusion imaging modalities on both patient and
oronary artery territory levels are summarized in Table 1.
he patient-based analyses show similar pooled sensitiv-
ties for the 3 modalities and differences in pooled
pecificities. Meta-regression resulted in significantly in-
reased RDORs for CMR and PET studies when com-
ared with SPECT studies. When comparing PET with
MR studies, the RDOR for PET was not significantly
ncreased. The RDOR was 1.44 (95% CI: 0.62 to 3.34;
 0.39) for patient-based analysis and 0.95 (95% CI:
.42 to 2.18; p  0.91), for coronary territory-based
) cardiac magnetic resonance (CMR); and (C) positron emission tomography
display of diagnostic accuracy with summary receiver-operating characteristics
ectly proportional to the sample size of the study. The area under the curve
and 1, with higher values indicating better test performance. The AUC was
urves for direct comparison of the diagnostic performance of SPECT (green line),CT); (B
raphic
dot dir
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ROC c
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May 8, 2012:1719–28 Diagnostic Performance of SPECT, CMR, PET Perfusionanalysis. The diagnostic performance of SPECT, CMR,
and PET to detect CAD on a patient-based level is
summarized in Figure 2.
Differences in the distribution of study characteristics
potentially affecting the diagnostic performance of the
imaging modalities are shown in Table 2. The I2 index
shows substantial heterogeneity for SPECT and CMR
(I2 63.6% and 58.3%, respectively). Subgroup analyses
ere performed to identify sources of variation between
tudy results (Tables 3, 4, and 5) and to evaluate whether
ifferences in distribution of study characteristics be-
ween modalities affect the comparison of the 3 modali-
ies. The analyses revealed no significant effect of test and
tudy characteristics on the diagnostic performance of the
modalities, except for a lower pooled DOR of SPECT
tudies using dipyridamole in comparison to adenosine.
he CMR studies with dipyridamole also reported a
ower diagnostic performance. The SPECT studies using
ttenuation correction demonstrated a lower sensitivity
nd higher specificity in comparison to studies without
ttenuation correction. Because of this decrease in sensi-
ivity, pooled DORs for SPECT studies with and with-
Distribution of Study Characteristics for SPECT, CMR, and PET PerTable 2 Distribution of Study Characteristics for SPECT, CMR,
Characteristic
SPECT Studies
(n  105)
CMR Studies
(n  27)
Mean n (%) Mean n (%)
Year of publication†
2006 1997 5 92 (88) 2006 2 11 (41
2006 13 (12) 16 (59
Mean age†
60, yrs 60 5 50 (47) 62 3 8 (30
60, yrs 48 (46) 19 (70
NS 7 (7) —
Study size†
70 129 204 45 (43) 92 84 15 (56
70 60 (57) 12 (44
Prevalence of CAD†
72% 70 15 50 (48) 59 17 18 (67
72% 55 (52) 9 (33
Prevalence of 3-vessel disease†
18% 18 10 37 (35) 14 10 14 (52
18% 41 (39) 5 (18
NS 27 (26) 8 (30
Cutoff value for CAD on invasive CA
50% — 88 (84) — 12 (44
70% 17 (16) 15 (56
Patient selection
Suspected CAD — 56 (53) — 18 (66
Suspected or known CAD 46 (44) 8 (30
Other 3 (3) 1 (4)
Verification bias
No — 44 (42) — 21 (78
Likely/yes 61 (58) 4 (15
Possible — 2 (7)
*Studies were only included in multivariable meta-regression if data on patient-based level and th
or greater than median.
CA  coronary angiography; CAD  coronary artery disease; NS  not specified; other abbreviations aut attenuation correction were similar. Four CMR studies
ere performed with 3.0-T scanners and reported a higher
iagnostic performance compared to studies using 1.5-T. For
PECT and PET studies, the pooled DOR for more recently
ublished studies (2006 or later) was lower than for studies
ublished before 2006. For SPECT and CMR studies, lower
ooled DORs were observed for studies with a larger sample
ize (70 patients) in comparison with studies with smaller
ample size. For SPECT, studies with a higher prevalence of
AD and 3-vessel disease were associated with a lower
iagnostic performance whereas CMR studies with a higher
revalence of CAD and 3-vessel disease showed a better
erformance than studies with a lower prevalence. Verification
ias had no impact on the pooled DORs of the 3 modalities.
he pooled sensitivity for studies with verification bias was
igher and the pooled specificity lower in comparison to
tudies without verification bias.
The diagnostic accuracy of PET and CMR in compari-
on with SPECT remained unchanged within the majority
f subgroup analyses. PET was consistently associated with
higher pooled DOR than CMR, whereas CMR demon-
trated a higher pooled DOR than SPECT. In a few
n Imaging Studies*PET Perfusion Imaging Studies*
PET Studies
(n  11)
SPECT Studies vs.
CMR Studies
SPECT Studies vs.
PET Studies
CMR Studies vs.
PET Studies
Mean n (%) p Value p Value p Value
01 8 5 (45) 0.001 0.16 0.05
6 (55)
61 4 3 (27) 0.12 0.52 0.72
6 (55)
2 (18)
69 49 7 (64) 0.36 0.34 0.41
4 (36)
81 8 1 (9) 0.05 0.05 0.001
10 (91)
26 12 1 (9) 0.11 0.06 0.05
5 (45)
5 (45)
— 9 (82) 0.001 0.87 0.07
2 (18)
— 4 (36) 0.19 0.34 0.08
7 (64)
—
— 6 (55) 0.001 0.53 0.10
5 (45)
—
rning study characteristic were available. †Cutoff values represent values less than and equal tofusioand
) 20
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
e conces in Table 1.
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Diagnostic Performance of SPECT, CMR, PET Perfusion May 8, 2012:1719–28subgroups, such as studies published in or after the year
2006, higher mean age, smaller sample size, and studies
using a cutoff value of 70% stenosis, CMR was associated
with a slightly higher pooled DOR than PET. The SPECT
and CMR studies reported similar pooled DORs in studies
with adenosine as stressor, lower mean age, and lower
prevalence of CAD and 3-vessel disease.
Direct comparisons. Few studies directly compared the
diagnostic accuracy of different imaging modalities within 1
study population. The study of Stewart et al. (Online Refer-
ence 95) reported an improvement of specificity to identify
CAD for rubidium-82 PET in comparison with thallium-201
SPECT. Furthermore, Doyle et al. (Online Reference 19) and
Subgroup Analyses for the Diagnostic Performance of SPECT on aTable 3 Subgroup Analyses for the Diagnostic Performance of
Characteristic Studies, n Sensitivity % (95% CI)
Stressor
Adenosine 12 91 (89–93)
Dipyridamole 15 85 (82–87)
Dobutamine 10 83 (80–86)
Treadmill exercise 22 90 (89–91)
Bicycle exercise 14 84 (82–86)
Tracer
Tl-201 39 89 (87–90)
99mTc MIBI 44 87 (85–88)
Rest Tl-201/stress 99mTc MIBI 7 88 (86–90)
99mTc tetrofosmin 7 79 (75–83)
Attenuation correction
Noncorrected 100 89 (88–89)
Corrected 5 80 (76–84)
Year of publication†
2006 92 89 (88–89)
2006 13 86 (84–88)
Mean age†
60, yrs 50 86 (85–87)
60, yrs 48 90 (89–91)
Study size†
70 45 86 (84–88)
70 60 89 (88–89)
Prevalence of CAD†
72% 50 85 (84–86)
72% 55 89 (89–90)
Prevalence of 3-vessel disease†
18% 37 86 (84–87)
18% 41 91 (90–91)
Cutoff value for CAD on CA
50% 88 87 (86–87)
70% 17 93 (92–94)
Patient selection
Suspected CAD 56 85 (84–86)
Suspected or known CAD 45 91 (90–92)
Verification bias
No 44 84 (83–86)
Likely/yes 61 90 (89–90)
*Studies were only included in multivariable meta-regression if data on patient-based level and th
or greater than median.
99mTc-MIBI  technetium-99m 2-methoxy-isobutyl-isonitrile; Tl-201  thallium-201; other abbSakuma et al. (Online Reference 83) investigated the diagnos- (tic accuracy of SPECT and CMR on a patient-based level and
found comparable diagnostic performance for both modalities.
Finally, Ishida et al. (Online Reference 45), Sakuma et al.
(Online Reference 83), and Thiele et al. (Online Reference
102) all reported a better diagnostic performance of CMR
perfusion imaging on a coronary territory-based analysis in
comparison with SPECT.
Publication bias. For SPECT and CMR studies, Egger’s
regression test showed significant funnel plot asymmetry
(intercept 2.17 [95% CI: 1.59 to 2.77]; p  0.001 for
PECT, intercept 1.58 [95% CI: 0.13 to 3.02]; p 0.03 for
MR), indicating that publication bias was likely. There
as no indication for funnel plot asymmetry in PET studies
nt-Based Level*T on a Patient-Based Level*
ificity % (95% CI) DOR (95% CI) RDOR (95% CI) p Value
78 (73–82) 31.02 (14.86–64.77) 1.00
72 (68–75) 11.36 (7.24–17.82) 0.40 (0.16–0.96) 0.04
74 (67–79) 17.62 (9.34–33.27) 0.61 (0.21–1.81) 0.36
59 (55–62) 15.51 (10.67–22.56) 0.70 (0.33–1.49) 0.34
69 (64–74) 13.25 (8.36–21.01) 0.45 (0.18–1.15) 0.09
71 (68–73) 19.88 (14.38–27.48) 1.00
68 (65–71) 14.91 (11.20–19.87) 0.78 (0.50–1.20) 0.25
54 (49–59) 11.11 (5.78–21.33) 0.60 (0.28–1.29) 0.18
72 (65–78) 10.26 (4.24–24.81) 0.49 (0.22–1.11) 0.09
60 (59–62) 15.39 (12.67–18.68) 1.00
78 (71–84) 13.18 (4.53–38.36) 0.75 (0.32–1.77) 0.51
61 (59–62) 16.23 (13.23–19.92) 1.00
62 (58–66) 10.55 (6.42–17.34) 0.64 (0.37–1.12) 0.12
72 (69–74) 15.42 (11.83–20.11) 1.00
54 (52–56) 15.97 (11.91–21.41) 1.01 (0.68–1.50) 0.97
75 (72–79) 17.64 (12.60–24.69) 1.00
58 (56–59) 14.32 (11.40–17.98) 0.85 (0.55–1.29) 0.44
73 (71–76) 16.86 (12.62–22.54) 1.00
49 (47–51) 14.02 (10.91–18.02) 0.93 (0.62–1.39) 0.71
75 (72–77) 19.05 (14.03–25.87) 1.00
47 (45–49) 14.96 (11.33–19.76) 0.87 (0.56–1.34) 0.52
69 (67–71) 16.04 (13.23–19.45) 1.00
43 (41–46) 11.81 (6.80–20.51) 0.70 (0.42–1.17) 0.17
69 (67–71) 14.46 (11.15–18.75) 1.00
51 (49–54) 16.25 (12.11–21.82) 1.19 (0.80–1.77) 0.39
73 (70–75) 15.06 (11.45–19.82) 1.00
55 (53–57) 15.00 (11.69–19.25) 0.99 (0.66–1.49) 0.97
rning study characteristic were available. †Cutoff values represent values less than and equal to
ns as in Tables 1 and 2.PatieSPEC
Spec
e conceintercept 0.01 [95% CI: 1.47 to 1.45]; p  0.99).
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May 8, 2012:1719–28 Diagnostic Performance of SPECT, CMR, PET PerfusionDiscussion
The prevalence of CAD is rising worldwide, and noninva-
sive myocardial perfusion imaging is increasingly being
performed to detect obstructive CAD, guide therapy, and
provide prognostic information (1–3,19). The current meta-
analysis revealed that the 3 most commonly used imaging
techniques for myocardial perfusion, SPECT, CMR, and
PET, can accurately detect obstructive CAD. Meta-
regression demonstrated that CMR and PET have a sig-
nificantly higher diagnostic accuracy than SPECT, on a
patient and coronary territory basis. A higher but nonsig-
nificant diagnostic performance was observed for PET in
comparison with CMR on a patient-based analysis, and a
similar diagnostic performance as CMR on coronary terri-
tory analysis. The diagnostic accuracy of PET and CMR in
comparison with SPECT remained unchanged within most
Subgroup Analyses for the Diagnostic Performance of CMR on a PaTable 4 Subgroup Analyses for the Diagnostic Performance of
Characteristic Studies, n Sensitivity % (95% CI) S
Stressor
Adenosine 21 90 (88–92)
Dipyridamole 3 84 (76–90)
Dobutamine 1 87
Nicorandil 1 94
Field strength
1.5-T 23 88 (87–90)
3.0-T 4 94 (89–98)
Data assessment
Qualitative 22 90 (88–91)
Semiquantitative 5 87 (81–91)
Year of publication†
2006 11 88 (85–91)
2006 16 90 (88–92)
Mean age†
60, yrs 8 85 (80–89)
60, yrs 19 90 (89–92)
Study size†
70 15 90 (87–93)
70 12 89 (87–91)
Prevalence of CAD†
72% 18 89 (86–91)
72% 9 89 (87–91)
Prevalence of 3-vessel disease†
18% 14 88 (84–90)
18% 5 90 (87–93)
Cutoff value for CAD on CA
50% 12 88 (86–90)
70% 15 90 (87–92)
Patient selection
Suspected CAD 18 89 (86–91)
Suspected or known CAD 8 90 (88–92)
Verification bias
No 21 89 (87–91)
Likely/yes 4 91 (85–95)
*Studies were only included in multivariable meta-regression if data on patient-based level and th
or greater than median.
Abbreviations as in Tables 1 and 2.subgroup analyses. Clinical validation studies showed thatadvances in attenuation correction lead to an increase in
specificity of SPECT with fewer false positive interpreta-
tions (20–22). Correspondingly, SPECT studies included
in this meta-analysis using attenuation correction reported a
higher overall specificity (Online References 6,23,26,28,37)
However, because of a decrease in sensitivity, this did not
result in an increase in overall diagnostic accuracy.
Although SPECT is the most widely used and validated
perfusion imaging technique, the advantage of PET over
SPECT could be explained by its higher spatial resolution,
excellent attenuation correction, and the use of different
tracers (13). Nevertheless, in spite of its high sensitivity and
specificity, widespread use of PET is currently hampered by
high costs and limited availability, although cost effective-
ness has been suggested (23).
In comparison to nuclear techniques, CMR perfusion im-
-Based Level*on a Patient-Based Level*
ity % (95% CI) DOR (95% CI) RDOR (95% CI) p Value
9 (76–82) 29.70 (21.00–42.01) 1.00
8 (71–83) 12.85 (2.65–62.30) 0.49 (0.17–1.40) 0.17
76
94
9 (76–81) 25.02 (17.13–36.56) 1.00
2 (72–89) 51.71 (22.44–119.15) 1.71 (0.55–5.30) 0.34
4 (71–77) 27.21 (17.97–41.22) 1.00
0 (74–85) 24.62 (6.95–87.28) 0.96 (0.32–2.93) 0.94
0 (76–84) 25.04 (13.07–47.97) 1.00
3 (69–76) 27.75 (16.31–47.23) 0.89 (0.36–2.18) 0.78
6 (70–80) 13.44 (7.23–24.99) 1.00
6 (72–79) 33.13 (20.97–52.34) 2.06 (0.84–5.03) 0.11
1 (76–86) 29.70 (19.08–46.25) 1.00
4 (70–77) 22.91 (12.24–42.87) 0.70 (0.30–1.59) 0.37
4 (70–77) 23.23 (13.10–41.17) 1.00
0 (75–85) 30.81 (21.58–43.98) 1.64 (0.71–3.78) 0.23
2 (68–76) 20.79 (11.08–39.02) 1.00
3 (77–88) 37.57 (22.69–62.21) 1.90 (0.67–5.43) 0.21
9 (76–83) 24.38 (16.93–35.11) 1.00
8 (74–82) 32.90 (16.79–64.47) 1.20 (0.59–2.44) 0.59
4 (71–77) 22.91 (13.49–38.92) 1.00
0 (74–84) 34.83 (20.70–60.45) 1.50 (0.60–3.73) 0.37
6 (73–79) 25.36 (15.81–40.70) 1.00
0 (61–78) 27.82 (10.70–72.33) 1.02 (0.29–3.67) 0.97
rning study characteristic were available. †Cutoff values represent values less than and equal totientCMR
pecific
7
7
7
8
7
8
8
7
7
7
8
7
7
8
7
8
7
7
7
8
7
7
e conceaging does not suffer from attenuation artefacts, provides the
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subendocardial perfusion deficits (24). However, only 3 tor 4
2-dimensional slices in short-axis view are usually imaged.
Another benefit of CMR, similar to PET, is the ability to
measure myocardial perfusion in absolute terms (25).
Currently, a multicomponent examination for CMR
imaging is used in clinical practice, which combines imaging
of myocardial perfusion and the presence and extent of
infarct scar with delayed gadolinium-enhancement (DE) to
detect CAD even more accurately (Online Reference 130).
Four studies included in this meta-analysis reported abso-
lute numbers on the diagnostic performance of CMR
perfusion in combination with DE-CMR in patients with-
Subgroup Analyses for the Diagnostic Performance of PET on a PatTable 5 Subgroup Analyses for the Diagnostic Performance of
Characteristic Studies, n Sensitivity % (95% CI) S
Stressor
Adenosine 2 90 (82–95)
Dipyridamole 3 88 (80–93)
Dipyridamole/handgrip 3 91 (87–94)
Exercise 1 96
Tracer
Rubidium-82 10 84 (81–87)
Copper-62 1 84
Acquisition
PET 8 82 (78–85)
PET/CT 3 91 (85–95)
Data assessment
Qualitative/ semiquantitative 9 90 (87–92)
Quantitative 2 52 (42–62)
Year of publication†
2006 5 91 (87–94)
2006 6 76 (70–81)
Mean age†
60 yrs 3 89 (82–95)
60 yrs 6 76 (71–80)
Study size†
70 7 75 (70–80)
70 4 90 (86–93)
Prevalence of CAD†
72% 1 93
72% 10 83 (80–86)
Prevalence of 3-vessel disease†
18% 1 85
18% 5 92 (89–95)
Cutoff value for CAD on CA
50% 9 82 (79–86)
70% 2 89 (82–94)
Patient selection
Suspected CAD 4 91 (87–94)
Suspected or known CAD 7 77 (72–82)
Verification bias
No 6 80 (76–84)
Likely/yes 5 90 (86–94)
*Studies were only included in multivariable meta-regression if data on patient-based level and th
or greater than median.
Abbreviations as in Tables 1 and 2.out a known prior myocardial infarction (Online References128–131). The reported sensitivities for this combined
approach ranged from 84% to 92%, and the specificities
from 57% to 88%. Combined approaches are also being
implemented for PET (26) and SPECT (27) with inte-
grated CT angiography to assess coronary anatomy.
Current research suggests that CT perfusion imaging has
the potential to evaluate qualitative and quantitative myo-
cardial blood flow (28), and stress myocardial perfusion
echocardiography has also been performed for the detection
of obstructive CAD, possibly with similar diagnostic accu-
racy as SPECT (29). An adenosine stress echocardiography
study combining wall motion and myocardial contrast
perfusion revealed a good diagnostic accuracy compared to
Based Level*n a Patient-Based Level*
ity % (95% CI) DOR (95% CI) RDOR (95% CI) p Value
8 (62–98) 43.34 (9.18–204.68) 1.00
1 (72–99) 48.14 (12.76–181.59) 0.87 (0.01–101.91) 0.91
3 (72–90) 46.88 (22.13–99.29) 1.08 (0.02–47.73) 0.94
89
1 (74–87) 36.56 (21.37–62.55)
100
6 (78–92) 44.31 (23.93–82.06) 1.00
7 (49–81) 21.07 (7.49–59.26) 0.42 (0.09–1.97) 0.23
1 (74–88) 41.08 (23.25–72.57) 1.00
8 (62–98) 15.50 (2.06–116.43) 0.41 (0.06–2.99) 0.33
4 (74–91) 48.84 (24.30–98.17) 1.00
8 (66–87) 24.57 (10.91–55.33) 0.50 (0.14–1.77) 0.24
9 (73–97) 48.93 (15.86–150.93) 1.00
1 (69–90) 24.84 (10.21–60.42) 0.51 (0.08–3.06) 0.39
7 (65–87) 24.23 (10.68–54.96) 1.00
4 (75–91) 48.90 (24.44–97.83) 2.03 (0.57–7.27) 0.23
50
6 (79–92) 44.18 (24.92–78.33)
91
1 (70–89) 47.16 (22.84–97.40)
5 (78–91) 42.51 (23.25–77.73) 1.00
9 (51–83) 24.49 (4.84–124.01) 0.50 (0.11–2.29) 0.32
7 (67–85) 34.41 (16.93–69.92) 1.00
0 (79–97) 39.61 (16.31–96.18) 1.14 (0.29–4.57) 0.83
5 (76–91) 39.76 (20.12–78.58) 1.00
7 (64–87) 31.96 (13.78–74.12) 0.80 (0.22–2.96) 0.70
rning study characteristic were available. †Cutoff values represent values less than and equal toient-PET o
pecific
8
9
8
8
8
6
8
8
8
7
8
8
7
8
8
8
8
6
7
9
8
7
e conceCMR perfusion (30). We could not include the perfusion
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meta-analysis because of the very limited number of studies
that met our inclusion criteria.
In contrast, stress echocardiography is widely performed to
detect regional wall motion abnormalities in patients with obstruc-
tive CAD with a diagnostic accuracy comparable to that of
SPECT, with a sensitivity of 40% to 100% and specificity of 62%
to 100% (31). However, considering the objectives of this study
and given the already large body of publications on myocardial
perfusion imaging with SPECT, CMR, and PET, we performed
a meta-analysis of perfusion imaging only and could not include
imaging techniques beyond perfusion.
This is the first meta-analysis that directly compares the 3
most commonly used techniques for perfusion imaging,
SPECT, CMR, and PET. The current study also provides a
considerable update to previously conducted meta-analyses on
individual modalities (11–14). However, we excluded several
studies that were used in previous meta-analyses because: 1) we
were not able to derive 22 contingency tables from the
published data (2 CMR and 3 PET studies); 2) we could not
distinguish the absolute numbers of patients from those in
healthy controls (1 SPECT study); 3) the study design was not
suitable (e.g., exclusively patients with left main/3-vessel dis-
ease or a multimodality approach was used to detect CAD)
(1 SPECT and 2 PET studies); or 4) the study was not published
in English (2 CMR studies). Overall, our results on sensitivity and
specificity of the individual perfusion imaging modalities on
patient-based and coronary territory-based analysis correspond
well to preceding meta-analyses of individual modalities.
In the current meta-analysis, CA was used as the refer-
ence standard for the detection of obstructive CAD, as CA
is traditionally considered the reference standard for the
detection and assessment of severity of CAD. However, this
invasive procedure is costly and not without risk. In addi-
tion, CA does not always provide sufficient information
regarding the hemodynamic relevance of a stenosis, given that
its presence does not necessarily result in a hemodynamic effect
on perfusion. Therefore, regarding anatomical information
from CA as the traditional reference standard could have
potentially biased our results. Invasively measured fractional
flow reserve detects the hemodynamic relevance of a stenosis more
accurately than anatomic imaging by CA (32). However, invasive
fractional flow reserve measurements were validated against PET
and SPECT as the reference standard (32,33). Studies that
compared CMR perfusion to fractional flow reserve also demon-
strated an excellent sensitivity and specificity to detect functionally
significant CAD (34) (Online References 121 and 134). An
interesting topic for future studies on reference standards would be
to assess the potential of noninvasive methods to quantitatively
measure perfusion such as PET.
The therapeutic and prognostic implications of nonob-
structive CAD are currently not fully understood. Although
Virmani et al. (35) already suggested that acute coronary
syndromes arise from (unstable) plaques and not necessarily
from severely stenosed coronary arteries, and myocardial
infarction can also occur in the absence of chronic coronaryobstructions as, for example, embolic infarctions (36), the
prognosis of patients with a negative SPECT, CMR, or
PET test is good (8–10) even though the presence of
plaques or minor coronary artery disease might not be
known. The event rate for cardiac death or nonfatal myo-
cardial infarction is as low as 1.1% per year in patients with
a stenosis of 50% on invasive CA, whereas an increasing
degree of stenosis is associated with an increasing risk for
myocardial infarction (37–39).
Finally, as with any meta-analysis, limitations to the meth-
ods include heterogeneity between studies and presence of
publication bias. Subgroup analyses demonstrated that most
test and study characteristics did not significantly affect the
diagnostic performance of the imaging modalities. However,
the power to detect relevant differences between subgroups
may have been limited by small numbers of studies in specific
subgroups. The largest merit of the subgroup analyses was that
differences in the distribution of test and study characteristics
did not affect the comparison of the 3 modalities. Within most
subgroup analyses, a relative superiority of PET and CMR
over SPECT was observed. More extensive exploration of
sources of heterogeneity with multivariable meta-regression
analysis to enable simultaneous correction for 1 study char-
acteristic was also not feasible because of the relatively small
number of PET studies. By applying Egger’s regression test,
publication bias was suggested for SPECT and CMR. It is
possible that small studies with low diagnostic performance
remained unpublished (40,41).
Conclusions
Our meta-analysis revealed that SPECT, CMR, and PET
all yielded a high sensitivity for the detection of obstructive
CAD, with a wide range of specificity. Both CMR and
PET showed a significantly higher diagnostic accuracy than
SPECT. While PET demonstrated the highest diagnostic
performance in a limited number of studies with small study
populations and a high prevalence of CAD, SPECT imag-
ing is widely available and most extensively evaluated. CMR
perfusion imaging may provide an alternative without the
use of ionizing radiation at a similar diagnostic accuracy as
PET. We suggest that referring physicians consider these
findings in the context of local expertise and infrastructure.
Future technical developments are likely to improve diag-
nostic performance of all 3 modalities by combined imaging
of prior myocardial infarction, coronary anatomy including
plaque morphology, and myocardial perfusion.
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